Evidence map›Paper›PMID 33442407›Full record

ReviewJournal of Cancer2021

Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields.

Shiyu Liu, Qin Zhao, Weiyan Shi, Zhuangzhuang Zheng, Zijing Liu, Lingbin Meng, Lihua Dong, Xin Jiang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shiyu LiuDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China.
Qin ZhaoDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China.
Weiyan ShiDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China.
Zhuangzhuang ZhengDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China.
Zijing LiuDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China.
Lingbin MengDepartment of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Lihua DongDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China.
Xin JiangDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun 130021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade gliomas (HGGs) are the most common primary malignant brain tumors. They have a high degree of malignancy and show invasive growth. The personal treatment plan for HGG is based on the patient's age, performance status, and degree of tumor invasion. The basic treatment plan for HGG involves tumor resection, radiotherapy (RT) with concomitant temozolomide (TMZ), and adjuvant TMZ chemotherapy. The basic radiation technology includes conventional RT, three-dimensional conformal RT, intensity-modulated RT, and stereotactic RT. As our understanding of tumor pathogenesis has deepened, so-called comprehensive treatment schemes have attracted attention. These combine RT with chemotherapy, molecular targeted therapy, immunotherapy, or tumor-treating fields. These emerging treatments are expected to improve the prospects of patients with HGG. In the present article, we review the recent advances in RT and comprehensive treatment for patients with newly diagnosed and recurrent HGG.

Indexed as

High-grade gliomaImmunotherapyMolecular targeted drugsRadiotherapyTumor-treating fields

Identifiers

PMID33442407
PMCPMC7797642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.